AlaskaDenise
In Memoriam
This article is primarily about a new drug under development that shows considerable success.
--------------------------------------------------------------------------------
Mar 21, 2011 – Immune Network Ltd. (IMMFF
K), is proud to announce that Immunitor co-organized and participated in an international scientific workshop dedicated to “NEW TECHNOLOGIES IN MEDICINE AND EXPERIMENTAL BIOLOGY” (IW+SDC’11) held this week in Rio de Janeiro, Brazil. Co-organized by Russian Academy of Sciences and biotechnology companies.....
(snipped)
After AIDS, tuberculosis is the second most common cause of death from an infectious disease, with approximately 1.7 million people dying each year, and 9 million individual acquiring new infections. Current treatments are not fully effective, particularly against multi-drug resistant TB (MDR-TB) and HIV-TB and strenuous treatment regimens lasting for up to 2 years are required. “Immunitor’s approach has the potential to address current challenges – offering shorter and safer treatment solution. V5 is inexpensive; easy to administer; does not require refrigeration; and is made from readily available sources, which suits ideally BRIC countries which include Brazil, Russia, India and China, where TB is rampant and patients are often too poor to afford expensive 2nd line TB drugs” said Vichai Jirathitikal, co-founder and co-inventor of Immunitor oral vaccine platform.
Read more at: http://www.inewsconnect.com/a/tuberculosis-second-biggest-killer-in-infectious-diseases/122173/
.
--------------------------------------------------------------------------------
Mar 21, 2011 – Immune Network Ltd. (IMMFF
K), is proud to announce that Immunitor co-organized and participated in an international scientific workshop dedicated to “NEW TECHNOLOGIES IN MEDICINE AND EXPERIMENTAL BIOLOGY” (IW+SDC’11) held this week in Rio de Janeiro, Brazil. Co-organized by Russian Academy of Sciences and biotechnology companies.....(snipped)
After AIDS, tuberculosis is the second most common cause of death from an infectious disease, with approximately 1.7 million people dying each year, and 9 million individual acquiring new infections. Current treatments are not fully effective, particularly against multi-drug resistant TB (MDR-TB) and HIV-TB and strenuous treatment regimens lasting for up to 2 years are required. “Immunitor’s approach has the potential to address current challenges – offering shorter and safer treatment solution. V5 is inexpensive; easy to administer; does not require refrigeration; and is made from readily available sources, which suits ideally BRIC countries which include Brazil, Russia, India and China, where TB is rampant and patients are often too poor to afford expensive 2nd line TB drugs” said Vichai Jirathitikal, co-founder and co-inventor of Immunitor oral vaccine platform.
Read more at: http://www.inewsconnect.com/a/tuberculosis-second-biggest-killer-in-infectious-diseases/122173/
.